A P P E N D I X

MARKED-UP VERSION SHOWING CHANGES

IN THE CLAIMS:

Claims 52, 67, 88-94 and 99-100 are being cancelled.

The claims are amended as follows:

Claim 45. (Amended) A process for treating an eye, comprising:

topically applying an azalide antibiotic to an eye in an amount effective to treat or prevent infection in a tissue of the eye, wherein said topically applying comprises supplying a depot of a composition containing said azalide antibiotic on the eye.

Claim 47. (Amended) The process according to claim 45, wherein said azalide antibiotic [comprises] is a compound of formula (I):



(I)

wherein R^1 and R^2 each independently represent a hydrogen atom or methyl group.

Claim 48. (Amended) The process according to claim 47, wherein said azalide antibiotic [comprises] is azithromycin.

Claim 49. (Amended) The process according to claim 45, wherein said [application] applying provides a therapeutically effective concentration of azalide antibiotic within a tissue of the eye for at least 8 hours.

Claim 50. (Amended) The process according to claim 49. wherein said [application] applying provides a therapeutically effective concentration of azalide antibiotic within a tissue of the eye for at least 12 hours.

Claim 51. (Amended) The process according to claim 50, wherein said [application] applying provides a therapeutically effective concentration of azalide antibiotic within a tissue of the eye for at least 18 hours.

Claim 53. (Amended) The process according to claim [52] 45, wherein said depot is an aqueous polymeric suspension of said azalide antibiotic.

Claim 56. (Amended) The process according to claim [52] 45, wherein said depot is a composition selected from the group consisting of an aqueous suspensions, ointments, and inserts.

Claim 59. (Amended) The process according to claim [52] 45, wherein said depot remains for at least 30 minutes after administration.

Claim 61. (Amended) [An] A topical ophthalmic composition comprising an aqueous polymeric suspension comprising water, 0.01% to 1.0% of an azalide antibiotic and 0.1 to 10% of a polymeric suspending agent.

Claim 62. (Amended) The [suspension] composition according to claim 61, wherein said suspension further [comprising] comprises an additional medicament selected from the group

B

consisting of antibiotics, antivirals, antifungals, anesthetics, anti-inflammatory agents, and anti-allergic agents.

Claim 63. (Amended) The [suspension] composition according to claim 62, wherein said additional medicament is contained in the amount of from 0.01 to 5.0%.

Claim 64. (Amended) The [suspension] composition according to claim [61] 62, wherein said additional medicament is selected from the group consisting of amikacin, gentamycin, tobramycin, streptomycin, netilmycin, kanamycin, ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, enoxacin, sulfonamides, polymyxin, chloramphenicol, neomycin, paramomomycin, colistimethate, bacitran, vancomycin, tetracyclines, rifampins, cycloserine, beta-lactams, cephalosporins, amphotericins, fluconazole, flucytosine, matamycin, miconazole, ketoconazole, corticosteroids, diclofenac, flurbiprofen, ketorolac, suprofen, comolyn, lodoxamide, levocabastin, naphazoling, antazoline, and pheniramimane.

Claim 65. (Amended) A topical ophthalmic composition comprising an effective amount of an azalide antibiotic, [and] an ophthalmically acceptable carrier, and an additional medicament selected from the group consisting of antibiotics, antivirals, antifungals, anesthetics, anti-inflammatory agents, and anti-allergic agents.

Claim 66. (Amended) The composition according to claim 65, wherein said azalide antibiotic [comprises] is azithromycin.

Claim 68. (Amended) The composition according to claim [67] 65, wherein said composition is fluid; said azalide antibiotic is contained in an amount of from about 0.01 to 2.0%;

B

and said additional medicament is contained in an amount of from about 0.01 to 5.0%.

Claim 73. (Amended) The process according to claim 70, wherein said [topical application] topically applying comprises supplying a depot of a composition containing said azalide antibiotic on the eye.

Claim 83. (Amended) The process according to claim 70, wherein said azalide antibiotic [comprises] is a compound of formula (I):



(I)

wherein R^1 and R^2 each independently represent a hydrogen atom or methyl group.

Claim 84. (Amended) The process according to claim 83, wherein said azalide antibiotic [comprises] is azithromycin.

Claim 85. (Amended) The process according to claim 70, wherein said [application] applying provides a therapeutically effective concentration of azalide antibiotic within a tissue of the eye for at least 8 hours.

Claim 86. (Amended) The process according to claim 85, wherein said [application] applying provides a therapeutically

effective concentration of azalide antibiotic within a tissue of the eye for at least 12 hours.

Claim 87. (Amended) The process according to claim 86, wherein said [application] applying provides a therapeutically effective concentration of azalide antibiotic within a tissue of the eye for at least 18 hours.

Claim 97. (Amended) The composition according to claim [67] 65, wherein said composition is fluid; said azalide antibiotic is contained in an amount from at least about 5.0%, and said additional medicament is contained in an amount of from about 0.01 to 5.0%.

Claim 98. (Amended) The composition according to claim [67] 65, wherein said composition is fluid; said azalide antibiotic is contained in an amount from about 0.1 to about 5.0%, and said additional medicament is contained in an amount of from about 0.001 to 5.0%.

Claim 101. (Amended) [An] A topical ophthalmic composition comprising an aqueous polymeric suspension comprising water, at least about 5.0% of an azalide antibiotic, and 0.1 to 10% of a polymeric suspending agent.

Claim 102. (Amended) [An] A topical ophthalmic composition comprising an aqueous polymeric suspension comprising water, from about 0.1 to about 5.0% of an azalide antibiotic, and 0.1 to 10% of a polymeric suspending agent.

B